Clinical Trial Update: A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for MSC2156119J (c-Met inhibitor) in Japanese subjects with solid tumors; study completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MSC2156119J (MSC2156119J)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2016-12-07